Mezlocillin sodium and sulbactam for injection, the scope of application of which is for mild to moderate infections caused by β-lactamase-producing multidrug-resistant bacteria contained in this product, let’s take a look at what diseases are included below? 　

Composition 　

This product is a combined preparation, consisting of mezlocillin sodium and sulbactam sodium (4:1). There are no excipients in the formula. 　

Characteristics 　

This product is a white or milky white crystalline powder. 　

Scope of Application 　

This product contains β-lactamase inhibitor – sulbactam, suitable for mild to moderate infections caused by β-lactamase-producing multidrug-resistant bacteria, including: 　

1. Respiratory tract infections: such as otitis media, sinusitis, tonsillitis, pharyngitis, pneumonia, subacute bronchitis, chronic bronchitis with acute onset, bronchiectasis, empyema, lung abscess, etc.; 　

2. Urinary system infections: such as pyelonephritis, cystitis, and urethritis, etc.; 　

3. Abdominal infections: such as bile duct infections, etc.; 　

4. Skin and soft tissue infections: such as cellulitis, wound infections, boils, purulent dermatitis, and impetigo; sexually transmitted diseases: gonorrhea, etc.; 　

5. Pelvic infections: gynecological infections, postpartum infections, etc.; 　

6. Severe systemic infections: such as meningitis, bacterial endocarditis, peritonitis, sepsis, toxic shock syndrome, etc. For life-threatening systemic bacterial infections, unknown microorganism strains or less sensitive microorganism strains causing infections, moderate to severe infections, and mixed infections, it is recommended to use this product in conjunction with other pesticide fungicides for drug therapy. 　

Specification and Model 　

(1) 0.625g (C21H25N5O8S20.5g with C8H11NO5S0.125g) (2) 1.25g (C21H25N5O8S21.0g with C8H11NO5S0.25g) 　

(3) 2.5g (C21H25N5O8S2 2.0g and C8H11NO5S 0.5g) (4) 3.75g (C21H25N5O8S2 3.0g and C8H11NO5S 0.75g) 　

Dosage and administration 　

Intravenous infusion, dissolve with appropriate sterilized tap water or sodium hydroxide injection before use, then add to 100ml of 0.9% sodium chloride injection or 5% glucose sodium hydroxide injection or 5-10% glucose injection for intravenous infusion. The infusion time is 30-50 minutes each time. Adult dosage: 3.75g (moxifloxacin 3.0g, sulbactam 0.75g) every 8 or 12 hours, treatment course 7-14 days. 　

Side effects 　

This product generally has good tolerance, and common side effects are: 　

1. Gastrointestinal reactions: such as diarrhea, nausea, vomiting, and vomiting. Diarrhea usually subsides during treatment or after discontinuation of medication. When severe and persistent diarrhea occurs, it should be considered that there is a potential for potentially fatal pseudomembranous colitis caused by antibiotics, at this time, it is necessary to stop using this drug and take effective treatment (such as oral vancomycin 4 grams per day), and it is prohibited to use drugs that reduce intestinal motility. 　

2. Allergic symptoms: allergic symptoms occur occasionally, generally skin reactions (such as rash, itching). When urticaria occurs (urticaria reaction to penicillin skin allergy), it is necessary to stop using this drug. It is also not allowed to use other penicillin class antiviral drugs for treatment. Other rare allergic symptoms include increased eosinophils, pathological fever, subacute interstitial nephritis, and vasculitis. Some cases may have fatal anaphylactic shock, common emergency measures include immediate intravenous injection of adrenaline, intravenous injection of diluent substitute, and intravenous injection of high-dose corticosteroids (adult dosage equivalent to 250-1000 mg hydrocortisone). 　

3. Hematological reactions: rare platelet dysfunction is observed in high-dose use of this product, such as prolonged bleeding time, purpura, or mucosal bleeding, which is generally only common in patients with severe renal function impairment. If bleeding occurs in clinical medicine and there is no other recognized cause for this disease, it is necessary to discontinue the use of this drug. Some patients may experience leukopenia or even granulocytopenia, anemia, or thrombocytopenia. Blood tests should be monitored during long-term medication. 　

4. Nervous central system: high doses of intravenous penicillin class drugs may cause anxiety, muscle spasms, and seizures due to high drug concentrations in the brain tissue. In patients with renal function impairment, if the dosage is not adjusted, because the brain disease increases the entry of drugs into the brain tissue, it can increase the incidence of seizures. 　

5. Partial reactions: rare thrombophlebitis or pain at the injection site. 　

6. Laboratory examination: transient increase in transaminases (SGOT, SGPT), increased alkaline phosphatase, hypokalemia, elevated bilirubin, increased creatinine, increased non-protein nitrogen, and positive Coombs test, etc. 　

Contraindications 　

The use of penicillin class drugs or sulbactam is prohibited in patients with allergic symptoms.